Guideline
A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel
Yi-Long Wu, Chang-Li Wang, Mei-Lin Liao, Zhong-Zhen Guan, Chen-Yan Gao, Shun Lu, Ming- Fang Zhao, Jie Wang, Xiao-Qing Liu, Jin-Ji Yang, Jun Liang, Wei-Min Mao, Bao-Hui Han, Xu- Chao Zhang, Yong Song, Ji-Feng Feng, Sheng-Lin Ma, Gang Wu, Cai-Cun Zhou, Ke-Neng Chen, Ying Cheng, Yong He, Chun Chen, Qun Wang, Ji-Zhen Lin, Bo Zhu, Yun-Peng Liu, Yi Hu, Gui-Bin Qiao, Qing Zhou, Qi-Bin Song, Nan Wu, Lin Wu, Cheng Huang, Xiao-Long Fu, Jian-Ping Xiong, Jie Hu, Cheng-Ping Hu, Jian-Hua Chang, Qiong Zhao, Jun Zhao, Peng- Hui Zhou, Zhi-Yong Ma, Yuan Chen, He-Long Zhang, Fan Yang, Jian-Jun Wang, Yue-Yin Pan, Xue-Ning Yang, Yun Fan, Zhe Liu, Wen Fan, Nong Yang, Yan-Fang Guan, Hao Sun, Wen-Zhao Zhong
Abstract
The notable clinical success of cancer immunotherapy using checkpoint blockade suggests that it is likely to form the foundation of curative therapy for many malignancies. However, checkpoint blockades do not achieve sustained clinical response in most patients and thus amounts of problems needed to be figured out. Regarding these challenges, the 2017 Chinese Lung Cancer Summit expert panel organized a forum on the 14th Chinese Lung Cancer Summit to formally discuss these controversies. Five consensuses finally were reached to guide the application of checkpoint blockades.
